Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 5,520,000 shares, a decline of 6.4% from the September 30th total of 5,900,000 shares. Based on an average daily volume of 1,650,000 shares, the short-interest ratio is presently 3.3 days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Fulcrum Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company's stock valued at $23,965,000 after acquiring an additional 18,681 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Fulcrum Therapeutics by 13.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company's stock valued at $9,182,000 after purchasing an additional 176,114 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Fulcrum Therapeutics by 54.3% during the first quarter. Jane Street Group LLC now owns 535,062 shares of the company's stock valued at $5,051,000 after purchasing an additional 188,212 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Fulcrum Therapeutics during the second quarter worth about $3,084,000. Finally, StemPoint Capital LP increased its stake in shares of Fulcrum Therapeutics by 8.1% in the first quarter. StemPoint Capital LP now owns 407,108 shares of the company's stock valued at $3,843,000 after buying an additional 30,535 shares during the period. Institutional investors and hedge funds own 89.83% of the company's stock.

Analysts Set New Price Targets

FULC has been the subject of several recent research reports. Bank of America cut shares of Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and reduced their target price for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Leerink Partnrs cut shares of Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 12th. Royal Bank of Canada cut shares of Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $15.00 to $4.00 in a report on Thursday, September 12th. Stifel Nicolaus downgraded Fulcrum Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Fulcrum Therapeutics presently has an average rating of "Hold" and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC traded down $0.07 during mid-day trading on Thursday, reaching $3.17. The company had a trading volume of 290,978 shares, compared to its average volume of 994,591. The firm has a market cap of $197.81 million, a price-to-earnings ratio of -1.99 and a beta of 2.21. The business's 50-day simple moving average is $5.04 and its 200 day simple moving average is $6.80. Fulcrum Therapeutics has a one year low of $2.87 and a one year high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.93. The firm had revenue of $80.00 million for the quarter, compared to analyst estimates of $80.00 million. During the same quarter in the prior year, the business posted ($0.38) EPS. On average, sell-side analysts anticipate that Fulcrum Therapeutics will post -0.28 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.